The United Bio-technology (hengqin) Co., Ltd.

This Phase 3 trial tests a new injection called UBT251 in 360 adults with type 2 diabetes who have not been able to control their blood sugar with diet and exercise alone. Participants will receive either a weekly shot of UBT251 (at different doses) or a placebo for several weeks…

This early-stage trial tests a single injection of UBT38006 in 43 healthy adult men to see if it is safe and how the body processes it. Participants receive either the drug, a placebo, or an active comparator (insulin degludec). The goal is to gather safety data and measure drug …

This phase 3 study compares an experimental weekly injection called UBT251 to the approved drug semaglutide in adults with type 2 diabetes whose blood sugar is not well controlled by oral medications like metformin. The main goal is to see if UBT251 is at least as effective as se…

This study tests a weekly injection called UBT251 in 180 overweight or obese adults with chronic kidney disease. The goal is to see if it can reduce protein in the urine (a sign of kidney damage) and help with weight control. Participants will receive either the drug or a placebo…

This study tests a new drug called UBT251, given as a weekly injection, for people with MASH (a serious fatty liver disease with scarring). 156 adults will be randomly assigned to receive one of three doses of UBT251 or a placebo for 48 weeks. The main goal is to see if the drug …

This early-stage trial is investigating whether an investigational drug called UBT251, given by injection, changes how the body processes four common oral medications: metformin (for diabetes), warfarin (a blood thinner), atorvastatin (for cholesterol), and digoxin (for heart con…